MA-TAKEDA-PHARMACEUTICAL
31.5.2022 14:02:07 CEST | Business Wire | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it will present data at two upcoming scientific congresses this spring: the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO) , June 3-7 in Chicago, Ill. and the 30th Congress of the European Hematology Association (EHA) , June 9-12 in Vienna, Austria. Takeda’s latest research in oncology focuses on enhancing and improving patient care while exploring novel approaches for patients with limited treatment options.
Data presentations span a range of cancers, including lymphoma, leukemia, multiple myeloma and non-small cell lung cancer, including early insights into investigational therapies that leverage the innate immune system.
“Our data at this spring’s medical congresses are indicative of our quest to outsmart cancer and our ability to work collaboratively with partners to further our research capabilities,” said Christopher Arendt, Ph.D., Head of Oncology Cell Therapy and Therapeutic Area Unit of Takeda. “In addition to sharing data on currently approved therapies, we look forward to presenting early findings from our innate immunity clinical programs – many of which are exploring novel mechanisms of action – that we believe have the power to advance the field of oncology and recast current standards of care.”
A full list of company-sponsored abstracts are available for ASCO and EHA .
Takeda’s Commitment to Oncology
Our core R&D mission is to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. Whether it’s with our hematology therapies, our robust pipeline, or solid tumor medicines, we aim to stay both innovative and competitive to bring patients the treatments they need. For more information, visit www.takedaoncology.com .
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK ) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220531005140/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tecnotree Strengthens LATAM Growth with New Digital Transformation Contracts Worth USD 8.8 Million27.7.2026 13:20:00 CEST | Press release
Tecnotree, a global leader in AI-native Digital Business Support Systems (BSS) and digital platform solutions, today announced it has secured new digital transformation contracts across Latin America with a combined value of USD 8.8 million, reinforcing the company’s continued commercial momentum and expanding its presence across one of its key strategic growth markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260727931342/en/ Tecnotree Strengthens LATAM Growth with New Digital Transformation Contracts Worth USD 8.8 Million Across the engagements, Tecnotree will deploy its AI-native digital platform and B2B Marketplace for enterprises to simplify customer and business operations through intelligent digital engagement, real-time monetization, digital commerce and partner ecosystem management and AI driven marketing and experience management. By providing a unified digital foundation, the platform enables communications
Pure Lithium Corporation Appoints Mercedes-Benz Battery Veteran Dr. Tobias Glossmann as Chief Product Officer27.7.2026 13:00:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated next-generation lithium metal battery company and developer of the patented Brine to Battery™ technology, today announced the appointment of Dr. Tobias Glossmann as Chief Product Officer. In this role, Dr. Glossmann will lead product and technology strategy, guiding the translation of Pure Lithium’s battery science into engineered products and directing the company’s product engineering efforts. Dr. Glossmann joins Pure Lithium after a 25-year career across Mercedes-Benz companies, most recently serving as Principal Systems Engineer at Mercedes-Benz Research & Development North America. His work spanned advanced battery technology development, from materials through complete battery systems, and he held companywide responsibility for high voltage safety. His career began in 2001 with battery systems development at DaimlerChrysler in Ulm, Germany, and later in Michigan, giving him more than two decades of experience across cell chemistry
Ohmium Appoints Hydrogen Veteran as Chief Commercial Officer27.7.2026 10:05:00 CEST | Press release
Ohmium International Inc., a leading manufacturer of cutting-edge, high-efficiency, modular Proton Exchange Membrane (PEM) electrolyzers, today announced the appointment of Mark Griffin as Chief Commercial Officer (CCO). Griffin will serve as the executive lead of the Ohmium Sales and Marketing organization, driving revenue growth, customer acquisition, and the expansion of a global ecosystem of developers, industrial collaborators, and strategic partners. His appointment brings fresh momentum to Ohmium’s commercial stance as green hydrogen transitions from early adoption into mainstream industrial deployment. Griffin brings over two decades of experience in energy, including work in hydrogen and renewables. At ScottishPower, he spent five years leading hydrogen market development and business energy sales, spearheading two multi-megawatt green hydrogen projects totaling more than £220 million. Both projects were government-subsidized and structured around 15-year decarbonization offta
Uptime Institute Partners with the Governorate of Nineveh to Advance Iraq’s Digital Infrastructure at the U.S.-Iraq Business Summit27.7.2026 09:02:00 CEST | Press release
A landmark partnership signed during Prime Minister Ali Al-Zaidi’s historic U.S. delegation positions Iraq for a new era of resilient, world-class digital infrastructure Uptime Institute today announced a landmark strategic partnership with the Governorate of Nineveh, signed at the U.S. Chamber of Commerce U.S.-Iraq Business Summit to accelerate the region’s digital transformation and advance Iraq’s national digital agenda. The agreement was signed on July 17, 2026, during the official U.S. visit of Iraqi Prime Minister Ali Al-Zaidi. Uptime Institute participated as part of the official delegation at a historic summit that yielded more than 50 agreements valued at over USD $60 billion, signaling a powerful new era of economic cooperation, investment, and technological innovation between the United States and Iraq. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260727139625/en/ Signing of landmark strategic partnership with A
Objectway Expands Into Capital Markets With Its Project to Acquire French Specialist SLIB, Pushing Forward Its Pan-European Growth Strategy27.7.2026 08:45:00 CEST | Press release
Strong complementary offering and expertise create new opportunities for strengthening strategic presence in France and broadening end-to-end proposition across key European markets.Key takeaways With this transaction, Objectway will extend its direct presence in France, adding another leading financial centre to its current footprint in major European hubs such as Italy, Germany, Switzerland, Benelux and the UK. Objectway will expand its offering across the investment services value chain, adding capital markets capabilities to its existing proposition for wealth management, private banking and asset management. SLIB will also broaden Objectway's client base with major European asset servicers, broker-dealers and banks, alongside strengthening Objectway's long-standing relationships with shared clients such as BNP Paribas. Objectway, the pan-European wealthtech solution partner for banking, wealth and asset management firms, today announced that it has entered into exclusive negotiati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom